Claims

1. Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament for the treatment and/or prevention of a disease selected from the group consisting of systemic lupus erythematosus and manifestations thereof, glomerulonephritis and nephropathy, preferably diabetic nephropathy;

whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144,

whereby the type A nucleic acid molecules comprise the following core nucleotide sequence:

5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

whereby X_A is either absent or is A,

whereby the type B nucleic acid molecules comprise the following core nucleotide sequence:

5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3' (SEQ.ID.No. 57), and

whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRX$_A$AGUCGG (SEQ.ID.No. 90),

whereby X_A is either absent or is A.

2. Use according to claim 1, wherein the L-nucleic acid molecule inhibits migration of leukocytes, dendritic cells and mast cells.

3. Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament for use in a method of treating and/or preventing a disease, wherein the method comprises inhibiting migration of leukocytes, whereby the nucleic acid molecule is selected

from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144,

whereby the type A nucleic acid molecules comprise the following core nucleotide sequence:

5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

whereby X_A is either absent or is A,

whereby the type B nucleic acid molecules comprise the following core nucleotide sequence:

5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3' (SEQ.ID.No. 57), and

whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRX$_A$AGUCGG (SEQ.ID.No. 90),

whereby X_A is either absent or is A.

4. Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament, whereby the medicament is for the treatment of a disease and/or disorder that involves angiogenesis and/or neovascularization, whereby the medicament is for use in combination therapy with an agent inhibiting VEGF or whereby the medicament is for use in a subject that does not respond to therapy with an agent inhibiting VEGF, and

whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144,

whereby the type A nucleic acid molecules comprise the following core nucleotide sequence:

5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

whereby X_A is either absent or is A,

whereby the type B nucleic acid molecules comprise the following core nucleotide sequence:

5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3' (SEQ.ID.No. 57), and

whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRX$_A$AGUCGG (SEQ.ID.No. 90),

whereby X_A is either absent or is A.

5. Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament, whereby the medicament is for restoration or improvement of an immune system in a subject and

whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144,

whereby the type A nucleic acid molecules comprise the following core nucleotide sequence:

5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

whereby X_A is either absent or is A,

whereby the type B nucleic acid molecules comprise the following core nucleotide sequence:

5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3' (SEQ.ID.No. 57), and

whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRX$_A$AGUCGG (SEQ.ID.No. 90),

whereby X$_A$ is either absent or is A.

6. Use of an L-nucleic acid molecule binding to SDF-1 for the manufacture of a medicament, whereby the medicament is for administration to a subject prior to or concomitant with chemotherapy, preferably chemotherapy administered for the treatment cancer,

whereby the nucleic acid molecule is selected from the group consisting of type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144,

whereby the type A nucleic acid molecules comprise the following core nucleotide sequence:

5' AAAGYRACAHGUMAAX$_A$UGAAAGGUARC 3' (SEQ.ID. 19)

whereby X$_A$ is either absent or is A,

whereby the type B nucleic acid molecules comprise the following core nucleotide sequence:

5' GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3' (SEQ.ID.No. 57), and

whereby the type C nucleic acid molecules comprise a core nucleotide sequence of GGUYAGGGCUHRX$_A$AGUCGG (SEQ.ID.No. 90),

whereby X$_A$ is either absent or is A.

7. The use according to any one of claims 1 to 6, wherein the nucleic acid molecule comprises a modification, whereby the modification is selected from the group comprising a HES moiety and a PEG moiety.

8. The use according to any one of claims 1 to 7, wherein the nucleic acid molecule is a type A nucleic acid molecule, whereby the type A nucleic acid molecule has a nucleic acid sequence according to any one of SEQ.ID.Nos. 5 to 18, 25 to 41, 133, 137 and 139 to 141.

9. The use according to any one of claims 1 to 7, wherein the nucleic acid molecule is a type B nucleic acid molecule, whereby the nucleic type B acid molecule has a nucleic acid sequence according to any one of SEQ.ID.Nos. 46 to 56, 61 to 72 and 132.

10. The use according to any one of claims 1 to 7, wherein the nucleic acid molecule is a type C nucleic acid molecule, whereby the type C nucleic acid molecule has a nucleic acid sequence according to any one of SEQ.ID.Nos. 79 to 89, 94 to 119, and 134 to 136.